The Ebola virus vaccine being used in the ongoing outbreak in the Democratic Republic of the Congo, or DRC, has been more than 97% effective, according to a preliminary estimate published by WHO.

The estimate comes from a ring trial of Merck’s experimental Ebola vaccine, V920, that is being conducted during the outbreak, in which contacts — and contacts of contacts — of confirmed cases are being offered vaccination. It was included in a report published on the heels of WHO’s announcement that it would not declare the outbreak, which now involves more than 1,200 confirmed or probable cases, an international public health emergency.

Credit: National Institute of Allergy and Infectious Diseases (NIAID)

Read more at Healio…